Recommendations from the EGAPP Working Group: does PCA3 testing for the diagnosis and management of prostate cancer improve patient health outcomes? | Zendy

Ned Calonge | Zendy; Roger D. Klein | Zendy; Jonathan S. Berg | Zendy; Doug CamposOutcalt | Zendy; Benjamin Djulbegović | Zendy; Théodore G. Ganiats | Zendy; A. Cecile J.W. Janssens | Zendy; Kenneth Offit | Zendy; Stephen G. Pauker | Zendy; Margaret Piper | Zendy; C. Sue Richards | Zendy; Ora L. Strickland | Zendy; Sean Tunis | Zendy; Marc S. Williams | Zendy; Doris T. Zallen | Zendy

Open Access

Recommendations from the EGAPP Working Group: does PCA3 testing for the diagnosis and management of prostate cancer improve patient health outcomes?

Author(s) -

Ned Calonge,

Roger D. Klein,

Jonathan S. Berg,

Doug CamposOutcalt,

Benjamin Djulbegović,

Théodore G. Ganiats,

A. Cecile J.W. Janssens,

Kenneth Offit,

Stephen G. Pauker,

Margaret Piper,

C. Sue Richards,

Ora L. Strickland,

Sean Tunis,

Marc S. Williams,

Doris T. Zallen

Publication year - 2013

Publication title -

genetics in medicine

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 3.509

H-Index - 128

eISSN - 1530-0366

pISSN - 1098-3600

DOI - 10.1038/gim.2013.141

Subject(s) - medicine , prostate cancer , overdiagnosis , rectal examination , pca3 , gynecology , psychological intervention , prostate specific antigen , population , prostate , oncology , cancer , intensive care medicine , psychiatry , environmental health

The Evaluation of Genomic Applications in Practice and Prevention (EGAPP) Working Group found insufficient evidence to recommend prostate cancer antigen 3 (PCA3) testing to inform decisions for when to rebiopsy previously biopsy-negative patients for prostate cancer or to inform decisions to conduct initial biopsies for prostate cancer in at-risk men (e.g., previous elevated prostate-specific antigen test or suspicious digital rectal examination).The EGAPP Working Group found insufficient evidence to recommend PCA3 testing in men with cancer-positive biopsies to determine if the disease is indolent or aggressive in order to develop an optimal treatment plan.Based on the available evidence, the overall certainty of clinical validity to predict the diagnosis of prostate cancer using PCA3 is deemed "low." The EGAPP Working Group discourages clinical use for diagnosis unless further evidence supports improved clinical validity.Based on the available evidence, the overall certainty of net health benefit is deemed "low." The EGAPP Working Group discourages clinical use unless further evidence supports improved clinical outcomes.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research